Targeted CDX2 expression inhibits aggressive phenotypes of colon cancer cells in vitro and in vivo.

In conclusion, overexpression of CDX2 using a hypoxia-inducible hTERT promoter-driven vector suppressed malignant progression of colon cancer cells in vitro and in vivo. These results suggest that pLVX-5HRE-hTERTp-CDX2-3FLAG gene therapy may be a promising novel approach to treat colon cancer. PMID: 28627695 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/28627695?dopt=Abstract

Source: International Journal of Oncology - June 13, 2017 Category: Cancer & Oncology Authors: Zheng J, He S, Qi J, Wang X, Yu J, Wu Y, Gao Q, Wang K, Sun X Tags: Int J Oncol Source Type: research